Teva CEO says Austedo can grow 'way beyond' impact of IRA

Nicole DeFeudis

Editor

Teva CEO Richard Francis said he expects sales growth to continue for the company’s top-selling drug Austedo, even after it becomes subject to new prices …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teva CEO says Austedo can grow 'way beyond' impact of IRA

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

Cargo Therapeutics cuts lead CAR-T program, 50% of staff

Takeda scraps programs as it raises full-year guidance

Roche aims for derisked deals and ruthless portfolio cuts in 2025

Sanofi is in the market for M&A, thanks to ‘strong’ balance sheet

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

Te­va CEO says Auste­do can grow 'way be­yond' im­pact of IRA

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Teva CEO says Austedo can grow 'way beyond' impact of IRA